Remove 2013 Remove Cannabis Remove Clinical Trials Remove Treatment
article thumbnail

Canada Opens Access for Psilocybin and MDMA Therapy

Cannabis Law Report

Subsection 56(1) of the CDSA will exempt medical providers from enforcement of the CDSA when providing psilocybin and MDMA treatment to patients suffering serious or terminal health conditions. In 2013, section C and J of Canada’s FDR statute were amended so that “restricted drugs” were inaccessible through SAP.

Therapy 52
article thumbnail

Realm of Caring Appoints Research Director to Oversee Groundbreaking Cannabis Data Registry and Medical Studies

Cannabis Law Report

The ORR is a web-based research platform open to adults and adult caregivers of dependents who are, or are considering, the use of cannabis or hemp products for therapeutic purposes. There are numerous obstacles to exploring the therapeutic potential of cannabis due to its classification as a Schedule I controlled substance,” Schlienz said.

Data 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cannabis and OCD: Seeking Relief

PrestoDoctor

While there are a variety of treatments available, many individuals do not find relief with traditional medications or therapies. However, recent research suggests that cannabis may be a promising option for those seeking relief from OCD symptoms. It is a serious medical condition that requires appropriate treatment and support.

article thumbnail

Press Release: Algernon Pharmaceuticals Completes Manufacturing of Psychedelic Drug DMT Appoints UK Stroke Experts for Phase 2

Cannabis Law Report

(the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPD) a clinical stage pharmaceutical development company is pleased to announce that it has completed the manufacturing of its clinical grade supply (“cGMP”) of AP-188 (“ N , N -Dimethyltryptamine or DMT”) at Canadian manufacturer Dalton Pharma Services.

article thumbnail

Canada: First patient in Quebec gets approval for magic mushroom therapy

Cannabis Law Report

When Thomas Hartle indulges in a session of psilocybin treatment, the end-of-life anxiety, distractions and noises associated with his terminal colon cancer go away. “Before the treatment, it’s like you’re sitting in your car. There must have been a lot of treatments done beforehand so the application is solid.”

Therapy 52
article thumbnail

Senators Call For Report On State Of Psychedelic Research

Cannabis Law Report

Widespread approval for psychedelic treatments remains unlikely, but the tide is slowly turning. In 2019, FDA approved Spravato (esketamine) nasal spray for treatment of depression in adults. [8] Clinical Trials and Human Subject Protections. For the regulated community, this is a trend worth watching. Davis et al.,

article thumbnail

Best strains and terpenes for pain management

The Cannigma

One of the most common uses of medical cannabis is to treat chronic pain. In fact, modern research on cannabis and pain dates back to before 1975. Over 10% of US adults have suffered from some degree of daily pain for at least three months, so the need for improved treatment is clear. How cannabis can help with pain.

Terpenes 111